Systemic Treatment of Thyroid Cancer Guideline
From ASCO Guidelines by American Society of Clinical Oncology (ASCO)
April 1, 2026 · 23 min
About this episode
Dr. Nabil Saba discusses the first evidence-based guideline on thyroid cancer from ASCO, covering treatment recommendations and the importance of shared decision-making.
Dr. Nabil Saba shares the first evidence-based guideline on thyroid cancer from ASCO. He highlights recommendations on first- and subsequent-line systemic treatment – including multikinase inhibitors (MKIs), genomically targeted therapies, immunotherapy, and cytotoxic chemotherapy across four subtypes of thyroid cancer: well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer. He dives into the evidence supporting each recommendation and explains the importance of shared decision-making on the risks and benefits of each treatment option. Dr. Saba also touches on outstanding questions including sequencing of agents, addressing resistance, emerging biomarker targets, and management of toxicities. Read the full guideline, " Systemic Treatment of Thyroid Cancer: ASCO Guideline ." TRANSCRIPT This guideline, clinical tools and resources are available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer . Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology. Brittany Harvey : Hello and welcome to the ASCO Guidelines podcast, one of…
People in this episode
Host: Brittany Harvey
Guest: Dr. Nabil Saba
Topics covered
- thyroid cancer
- systemic treatment
- evidence-based guidelines
- multikinase inhibitors
- immunotherapy
- shared decision-making
Keywords
- thyroid cancer
- systemic treatment
- ASCO guidelines
- multikinase inhibitors
- immunotherapy
- chemotherapy
- evidence-based medicine
Mentioned in this episode
Organizations: American Society of Clinical Oncology, Emory University, Journal of Clinical Oncology
Books & works: Systemic Treatment of Thyroid Cancer: ASCO Guideline
More episodes of ASCO Guidelines
- Patient-Clinician Communication Guideline Update · March 10, 2026 · 31 min
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Guideline Update · February 26, 2026 · 29 min
- White Blood Cell Growth Factors Guideline Update · February 25, 2026 · 23 min
- Therapy for Stage IV NSCLC With Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 2 · February 3, 2026 · 20 min
- Therapy for Stage IV NSCLC Without Driver Alterations: ASCO Living Guideline Update 2026.3.0 Part 1 · February 3, 2026 · 18 min
- Systemic Therapy in Patients With mCRPC: ASCO Living Guideline 2026.1 · January 20, 2026 · 14 min
Explore listener stats, chart rankings, contacts and more on the ASCO Guidelines podcast page.